{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:03:03Z","timestamp":1777366983374,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008743","name":"Ministerio de Educaci\u00f3n y Cultura","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005746","name":"Universidad Nacional del Litoral","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bioorg.2019.103372","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T02:46:22Z","timestamp":1572230782000},"page":"103372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay"],"prefix":"10.1016","volume":"94","author":[{"given":"Milagros","family":"B\u00fcrgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Cerecetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Kratje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Oggero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela","family":"Bollati-Fogol\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bioorg.2019.103372_b0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cytogfr.2006.07.001","article-title":"Interferon: the pathways of discovery I. Molecular and cellular aspects","volume":"17","author":"Billiau","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2019.103372_b0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2006.08.008","article-title":"Fifty years of interferon research: aiming at a moving target","volume":"25","author":"Vilcek","year":"2006","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bioorg.2019.103372_b0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonzalez-Navajas","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"Pt 10","key":"10.1016\/j.bioorg.2019.103372_b0020","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","article-title":"Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures","volume":"81","author":"Goodbourn","year":"2000","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.bioorg.2019.103372_b0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.coi.2011.06.003","article-title":"Systemic responses during local viral infections: type I IFNs sound the alarm","volume":"23","author":"Lopez","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2019.103372_b0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.bioorg.2019.103372_b0035","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.bioorg.2019.103372_b0040","unstructured":"S.G. Pandalai, Recent research developments in immunology Volume 6, 2004 Volume 6, 2004, Research Signpost, Trivandrum, 2004."},{"key":"10.1016\/j.bioorg.2019.103372_b0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0105-2896.2005.00252.x","article-title":"Interferons as pathogenic effectors in autoimmunity","volume":"204","author":"Baccala","year":"2005","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.bioorg.2019.103372_b0050","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2019.103372_b0055","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sjogren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"Suppl 1","key":"10.1016\/j.bioorg.2019.103372_b0060","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis","volume":"12","author":"Greenberg","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2019.103372_b0065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2009.03.012","article-title":"Interferons and autoimmune disorders","volume":"76","author":"Meyer","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bioorg.2019.103372_b0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2013.00266","article-title":"The role of type 1 interferon in systemic sclerosis","volume":"4","author":"Wu","year":"2013","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bioorg.2019.103372_b0075","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diab.44.6.658","article-title":"Interferon expression in the pancreases of patients with type I diabetes","volume":"44","author":"Huang","year":"1995","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.bioorg.2019.103372_b0080","first-page":"451","article-title":"Interferon alpha and its contribution to autoimmunity","volume":"7","author":"Selmi","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.bioorg.2019.103372_b0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2019.103372_b0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1042\/bst0310433","article-title":"The role of therapeutic antibodies in drug discovery","volume":"31","author":"Stockwin","year":"2003","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.bioorg.2019.103372_b0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mi.2.1.36","article-title":"Coming of age: anti-cytokine therapies","volume":"2","author":"Song","year":"2002","journal-title":"Mol. Interv."},{"issue":"3","key":"10.1016\/j.bioorg.2019.103372_b0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2013.02.013","article-title":"Anti-interferon alpha treatment in SLE","volume":"148","author":"Kirou","year":"2013","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bioorg.2019.103372_b0105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12033-010-9251-z","article-title":"Cell-based assays for high-throughput screening","volume":"45","author":"An","year":"2010","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.bioorg.2019.103372_b0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbiotec.2016.06.021","article-title":"Screening and characterization of molecules that modulate the biological activity of IFNs-I","volume":"233","author":"Burgi","year":"2016","journal-title":"J. Biotechnol."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2019.103372_b0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2012.04.010","article-title":"WISH cell line: from the antiviral system to a novel reporter gene assay to test the potency of human IFN-alpha and IFN-beta","volume":"381","author":"Burgi","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2019.103372_b0120","unstructured":"E. Martis, R. Radhakrishnan, R. Badve, High-throughput screening: The hits and leads of drug discovery \u2013 an overview J. Appl. Pharm. Sci. 1 (2011) 2\u201310."},{"issue":"2","key":"10.1016\/j.bioorg.2019.103372_b0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biopha.2007.06.012","article-title":"A review of high throughput technology for the screening of natural products","volume":"62","author":"Mishra","year":"2008","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2019.103372_b0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/ijms13010427","article-title":"Adaptation of high-throughput screening in drug discovery-toxicological screening tests","volume":"13","author":"Szymanski","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2019.103372_b0135","first-page":"1263","article-title":"A novel, quantitative bioassay for type I interferon using a recombinant indicator cell line","volume":"8","author":"Lleonart","year":"1990","journal-title":"Biotechnology (N Y)"},{"issue":"3","key":"10.1016\/j.bioorg.2019.103372_b0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1189\/jlb.0812395","article-title":"Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes","volume":"93","author":"Dickensheets","year":"2013","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2019.103372_b0145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1745-7254.2006.00292.x","article-title":"Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells","volume":"27","author":"Li","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2019.103372_b0150","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.biopha.2017.06.003","article-title":"An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances","volume":"92","author":"Zeinali","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.bioorg.2019.103372_b0155","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.apsb.2018.07.005","article-title":"High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway","volume":"8","author":"Yuliantie","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.bioorg.2019.103372_b0160","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1021\/jm500018m","article-title":"Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity","volume":"57","author":"Alvarez","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2019.103372_b0165","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1016\/j.ejmech.2009.06.014","article-title":"Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies","volume":"44","author":"Boiani","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2019.103372_b0170","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1016\/j.bmc.2010.05.033","article-title":"Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers","volume":"18","author":"Cabrera","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103372_b0175","doi-asserted-by":"crossref","unstructured":"F. Ferraro, A. Merlino, N. Dell Oca, J. Gil, J.F. Tort, M. Gonzalez, H. Cerecetto, M. Cabrera, I. Corvo, Identification of Chalcones as Fasciola hepatica Cathepsin L Inhibitors Using a Comprehensive Experimental and Computational Approach, PLoS Negl Trop Dis 10(7) (2016) e0004834.","DOI":"10.1371\/journal.pntd.0004834"},{"key":"10.1016\/j.bioorg.2019.103372_b0180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2012.10.047","article-title":"Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates","volume":"59","author":"Hernandez","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2019.103372_b0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0887-2333(89)90039-8","article-title":"Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs","volume":"3","author":"Saotome","year":"1989","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bioorg.2019.103372_b0190","unstructured":"P. Eur, European Pharmacopeia 6.3. Interferon Beta-1a Concentrated Solution. Council of Europe, (2009) Strasbourg, p. 4177."},{"key":"10.1016\/j.bioorg.2019.103372_b0195","unstructured":"J. Cornley, Design of experiments: useful statistical tool in assay development or vendor disconnect!, Winter 2009\/2010 <https:\/\/www.ddw-online.com\/drug-discovery\/p146741-design-of-experiments:-useful-statistical-tool-in-assay-development-or-vendor-disconnect.html>."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2019.103372_b0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.aca.2009.06.015","article-title":"Experimental design in chemistry: a tutorial","volume":"652","author":"Leardi","year":"2009","journal-title":"Anal. Chim Acta"},{"key":"10.1016\/j.bioorg.2019.103372_b0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.talanta.2014.01.034","article-title":"Experimental design and multiple response optimization. Using the desirability function in analytical methods development","volume":"124","author":"Candioti","year":"2014","journal-title":"Talanta"},{"issue":"3","key":"10.1016\/j.bioorg.2019.103372_b0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.antiviral.2008.12.004","article-title":"High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay","volume":"81","author":"Garcia","year":"2009","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.bioorg.2019.103372_b0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.micinf.2010.12.007","article-title":"Putting the brakes on the anti-viral response: negative regulators of type I interferon (IFN) production","volume":"13","author":"Richards","year":"2011","journal-title":"Microbes Infect"},{"issue":"7053","key":"10.1016\/j.bioorg.2019.103372_b0220","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2019.103372_b0225","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jir.2010.0079","article-title":"Novel nonviral bioassays for mouse type I and type III interferon","volume":"31","author":"Kugel","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.bioorg.2019.103372_b0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.aca.2015.01.017","article-title":"Practical guidelines for reporting results in single- and multi-component analytical calibration: a tutorial","volume":"868","author":"Olivieri","year":"2015","journal-title":"Analytica Chimica Acta"},{"issue":"17","key":"10.1016\/j.bioorg.2019.103372_b0235","doi-asserted-by":"crossref","first-page":"8626","DOI":"10.1128\/JVI.00303-10","article-title":"Temporal and spatial resolution of type I and III interferon responses in vivo","volume":"84","author":"Pulverer","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bioorg.2019.103372_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-1759(96)00168-8","article-title":"A highly precise reporter gene bioassay for type I interferon","volume":"199","author":"Canosi","year":"1996","journal-title":"J. Immunol. Methods"},{"issue":"11","key":"10.1016\/j.bioorg.2019.103372_b0245","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1515\/hsz-2016-0148","article-title":"Inhibition of interleukin-3- and interferon- alpha-induced JAK\/STAT signaling by the synthetic alpha-X-2',3,4,4'-tetramethoxychalcones alpha-Br-TMC and alpha-CF3-TMC","volume":"397","author":"Jobst","year":"2016","journal-title":"Biol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2019.103372_b0250","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of Type I and Type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819309605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819309605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:54:02Z","timestamp":1758614042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819309605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":50,"alternative-id":["S0045206819309605"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103372","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103372"}}